Aoife Brennan, serving as President and Chief Executive Officer of Climb Bio, Inc. (NASDAQ:CLYM), completed a transaction involving the sale of 30,902 shares of the company’s common stock on June 29, 2026. The aggregate value of this sale reached $406,979. The execution of these shares occurred at a weighted average price of $13.17, with specific transaction prices varying between $13.02 and $13.34. This divestment was facilitated under a pre-arranged 10b5-1 trading plan, which Ms. Brennan established on August 30, 2024. The primary purpose of this plan was to address tax withholding obligations linked to the vesting and settlement of her restricted stock units.
The timing of this sale aligns with Climb Bio shares trading in proximity to their 52-week high of $13.69. This price level follows a documented 952% gain over the preceding year. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value. Despite this valuation metric, analysts maintain price targets ranging from $15 to $35 per share. Two days prior to the sale, on June 27, 2026, Ms. Brennan acquired 68,750 shares of Climb Bio common stock. This acquisition resulted from the conversion of restricted stock units, where each unit converted into one share of common stock. These restricted stock units, representing a contingent right to receive shares, were granted on June 27, 2024, and are scheduled to vest over four years.
Following these transactions, Ms. Brennan directly holds 87,731 shares of Climb Bio common stock. This total includes an additional 1,751 shares previously acquired through the company’s Employee Stock Purchase Plan. She also retains 137,500 restricted stock units. In other recent developments, Climb Bio Inc. announced initial data from its Phase 1b/2a study of budoprutug, an anti-CD19 monoclonal antibody for treating primary immune thrombocytopenia in adults. The data, presented at the European Hematology Association Congress, showed promising results, with significant platelet responses and B-cell depletion observed in the trial’s 250mg cohort.
Following these developments, BTIG raised its price target for Climb Bio to $20, maintaining a Buy rating, while H.C. Wainwright reiterated its Buy rating and $20 price target. Guggenheim also initiated coverage on Climb Bio with a Buy rating and set a price target of $35. Climb Bio stock closed at $13.04, down $0.32 or 2.40% on the day. In the after-hours session, the stock traded at $13.04 with no change. Climb Bio held its annual stockholders’ meeting, where Alexander Cumbo and Douglas Williams were elected to the board of directors for three-year terms. Shareholders approved an amendment to the equity plan and ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.